Hester Biosciences Limited AI Stock Analysis
Want to see IN:HESTERBIO full AI Analyst Report?
Hester Biosciences Limited (HESTERBIO) AI Stock Analysis
Hester Biosciences Limited
(NSE:HESTERBIO)
The company's strong financial fundamentals, marked by a healthy balance sheet and consistent profitability, are the primary support for the score. However, this is significantly offset by weak technical momentum, as the stock trades below key moving averages with bearish indicators. Reasonable valuation provides a neutral-to-positive influence. The overall score reflects a fundamentally sound company currently facing negative market sentiment.
Hester Biosciences Limited (HESTERBIO) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 19.47B
- Dividend Yield
- 0.48%
- Average Volume (3M)
- 302
- Price to Earnings (P/E)
- 13.7
- Beta (1Y)
- 0.58
- Revenue Growth
- 17.48%
- EPS Growth
- 224.08%
- Country
- India
- Employees
- 483
- Sector
- General
- Sector Strength
- 55
- Industry
- Drug Manufacturers - Specialty & Generic
Hester Biosciences Limited Business Overview & Revenue Model
Company Description
Hester Biosciences Limited, founded in 1987 and headquartered in Ahmedabad, India, specializes in the production and commercialization of veterinary vaccines and a comprehensive array of animal health solutions. The company's operations span both dom...
Hester Biosciences Limited Financial Statement Overview
Summary
Overall financial health is sound, driven by a robust balance sheet (Score: 85) with significantly reduced leverage and steady equity growth. The income statement (Score: 78) shows consistent revenue growth and strong operational efficiency, though gross margin volatility is a minor concern. Cash flow (Score: 75) has strengthened, with positive free cash flow covering a healthy portion of net income.
Income Statement
78PositiveBalance Sheet
85Very PositiveCash Flow
75Positive| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.54B | 3.33B | 3.11B | 3.05B | 2.66B | 2.35B |
| Gross Profit | 2.11B | 1.69B | 2.08B | 972.64M | 1.89B | 1.66B |
| EBITDA | 1.12B | 866.58M | 649.76M | 582.46M | 619.20M | 731.93M |
| Net Income | 1.42B | 556.39M | 274.88M | 188.89M | 266.27M | 393.20M |
Balance Sheet | ||||||
| Total Assets | 6.83B | 6.78B | 6.53B | 6.62B | 6.70B | 5.62B |
| Cash, Cash Equivalents and Short-Term Investments | 272.37M | 65.38M | 72.19M | 153.04M | 148.17M | 252.20M |
| Total Debt | 1.09B | 1.95B | 2.13B | 2.44B | 2.74B | 2.28B |
| Total Liabilities | 2.08B | 3.10B | 3.27B | 3.59B | 3.81B | 2.95B |
| Stockholders Equity | 4.68B | 3.60B | 3.14B | 2.92B | 2.80B | 2.60B |
Cash Flow | ||||||
| Free Cash Flow | 0 | 417.03M | 439.20M | 237.37M | -541.66M | -869.02M |
| Operating Cash Flow | 0 | 595.31M | 645.11M | 481.34M | 235.96M | 88.08M |
| Investing Cash Flow | 0 | -49.00M | -190.03M | -226.54M | -769.99M | -1.17B |
| Financing Cash Flow | 0 | -421.53M | -517.17M | -260.45M | 417.58M | 1.12B |
Hester Biosciences Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:HESTERBIO, the sentiment is Positive. The current price of 2329.90 is above the 20-day moving average (MA) of 2255.54, above the 50-day MA of 2219.13, and above the 200-day MA of 1952.25, indicating a bullish trend. The MACD of 39.48 indicates Negative momentum. The RSI at 54.51 is Neutral, neither overbought nor oversold. The STOCH value of 29.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:HESTERBIO.
Hester Biosciences Limited Peers Comparison
Overall Rating
IN:VENUSREM72Outperform
IN:HESTERBIO67Neutral
IN:GUJTHEM59Neutral
IN:ZIMLAB52.5Neutral
IN:WANBURY48Neutral
IN:SIGACHI47Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 72Outperform | INR 20.83B | 17.14 | ― | 0.64% | 20.22% | 73.03% | |
| 67Neutral | INR 19.66B | 13.75 | ― | 0.48% | 17.48% | 224.08% | |
| 59Neutral | INR 46.82B | 80.37 | ― | 0.19% | 17.51% | 9.17% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 53Neutral | INR 7.47B | 263.90 | ― | ― | 13.14% | -60.77% | |
| 48Neutral | INR 6.23B | 11.75 | ― | ― | 7.45% | -6.56% | |
| 47Neutral | INR 10.78B | 42.98 | ― | 0.35% | -3.07% | ― |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:HESTERBIO | Hester Biosciences Limited | 2329.90 | 674.92 | 40.78% | |
| IN:SIGACHI | Sigachi Industries Limited | 28.61 | -6.70 | -18.97% | |
| IN:VENUSREM | Venus Remedies Limited | 1521.50 | 879.63 | 137.04% | |
| IN:WANBURY | Wanbury Limited | 177.45 | -50.75 | -22.24% | |
| IN:ZIMLAB | Zim Laboratories Ltd. | 135.85 | 61.68 | 83.16% | |
| IN:GUJTHEM | Gujarat Themis Biosyn Ltd | 348.80 | -87.54 | -20.06% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 14, 2026
